TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nutriband CEO Publishes Letter to Shareholders

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Gareth Sheridan, Ceo
Nutriband CEO Publishes Letter to Shareholders

Nutriband Inc. reported significant progress in 2025 including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M with no shareholder dilution, a 25% preferred stock dividend, and major advances in its lead product AVERSA Fentanyl abuse-deterrent patch. The company received FDA Type C Meeting approval, completed manufacturing scale-up, secured additional patents, and was added to four Russell indexes. The CEO highlighted shareholder value focus and anticipated warrant expiration in October 2026 as a potential positive catalyst.

Insights
BMLpL   neutral

The announcement indicates a strategic increase in financial instruments without explicit positive or negative implications, representing a neutral market movement


NTRB   positive

Company demonstrated strong progress toward commercialization of lead product AVERSA Fentanyl with FDA Type C Meeting approval, patent issuances, manufacturing scale-up completion, and strategic capital management through subsidiary sale without shareholder dilution. Addition to Russell indexes and preferred stock dividend also indicate positive momentum.